X

Gujarat Themis Biosyn Ltd Stock Analysis

Small Cap
Evaluated by 376 users | BSE: 506879 | NSE: GUJTHEMIS |
Pharmaceuticals & Drugs
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants. The company has world-wide exports to satisfied customers,...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed -2592.84%79.79%-369.62%200.09%115.77%79.15%48.05%33.43%34.83%64.96%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 13.58.728.430.231.432.635.738.841.185.1
Y-o-Y Gr. Rt.--35.5%225.7%6.6%4%3.8%9.4%8.7%5.8%107.4%
Adjusted EPS (Rs.) -2.86-2.160.693.113.33.213.012.664.3916.3
Y-o-Y Gr. Rt.-NANA350.7%6.1%-2.7%-6.2%-11.6%65%271.3%
Book Value per Share (Rs.) -13.32-11.95-6.79-3.68-0.542.655.658.3412.7529.04
Adjusted Net Profit -3.3-2.514.54.84.74.43.96.423.7
Net Op. Cash Flow (Rs. Cr.) 31.90.54.32.73.92.85.60.70.6
Debt to Cash Flow from Ops 4.556.1724.712.052.240.851.420.118.7612.92
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Gujarat Themis Biosyn Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 22.7%22%33.6%107.4%
Adjusted EPS NA37.6%75.6%271.3%
Book Value per Share 0072.6127.8
Share Price 47.4% 32.2% 69% 79.3%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 24.0217.11-8.42-59.39-156.7305.1172.4638.0841.6177.99
Operating Profit Margin (%) -8.37-26.3412.8221.5420.8718.6616.9516.0917.9437.4
Net Profit Margin (%) -24.57-28.793.5214.9415.2714.312.249.9715.5227.81
Debt to Equity -0.88-0.83-1.16-1.65-7.740.860.490.050.320.19
Working Capital Days 9416668565055787392144
Cash Conversion Cycle -74-74-44-54-52-47-26-22-1927
Entity Percentage Holding
Promoters 74.99%
Institutions 0.03%
Non-Institutions 24.97%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Gujarat Themis Biosyn Ltd's performance infers:

Gujarat Themis Biosyn Ltd earnings have grown by 37.6%, whereas share price has appreciated 32.2% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Gujarat Themis Biosyn Ltd share prices over the last 10 years. Here is what we found out:

Gujarat Themis Biosyn Ltd share price has appreciated 39.9% annually over the past ten years.

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process.

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company

  • Pharmaceuticals & Drugs
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback